CC-223

• CAT Number: I000885
• CAS Number: 1228013-30-6
• Molecular Formula: C21H27N5O3
• Molecular Weight: 397.5
• Purity: ≥95%
• Target: mTOR
• Solubility: DMSO: ≥ 27 mg/mL
• Storage: Store at -20°C
• IC50: 16 nM
• IUPAC Name: 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(4-methoxycyclohexyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one
• InChI: InChI=1S/C21H27N5O3/c1-21(2,28)17-9-4-13(10-22-17)16-11-23-19-20(25-16)26(18(27)12-24-19)14-5-7-15(29-3)8-6-14/h4,9-11,14-15,28H,5-8,12H2,1-3H3,(H,23,24)
• InChIKey: UFKLYTOEMRFKAD-UHFFFAOYSA-N
• SMILES: CC(C)(C1=NC=C(C=C1)C2=CN=C3C(=N2)N(C(=O)CN3)C4CCC(CC4)OC)O

CC 223（Cat No.:I000885） is a potent and selective mTOR inhibitor that can be administered orally. It exhibits an IC50 (half maximal inhibitory concentration) of 16 nM, indicating its strong inhibitory activity against the mammalian target of rapamycin (mTOR). By targeting mTOR, CC 223 disrupts the signaling pathways involved in cell growth, proliferation, and survival. This compound holds promise as a therapeutic agent in various diseases, including cancer, where dysregulated mTOR signaling plays a critical role.

Reference

1:CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo. Xie Z, Wang J, Liu M, Chen D, Qiu C, Sun K.PLoS One. 2017 Mar 23;12(3):e0173252. doi: 10.1371/journal.pone.0173252. eCollection 2017. PMID: 28334043 Free PMC Article2:A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN.Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422. Epub 2015 Jul 15. PMID: 26177599 Free PMC Article3:Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. Mortensen DS, Perrin-Ninkovic SM, Shevlin G, Zhao J, Packard G, Bahmanyar S, Correa M, Elsner J, Harris R, Lee BG, Papa P, Parnes JS, Riggs JR, Sapienza J, Tehrani L, Whitefield B, Apuy J, Bisonette RR, Gamez JC, Hickman M, Khambatta G, Leisten J, Peng SX, Richardson SJ, Cathers BE, Canan SS, Moghaddam MF, Raymon HK, Worland P, Narla RK, Fultz KE, Sankar S.J Med Chem. 2015 Jul 9;58(13):5323-33. doi: 10.1021/acs.jmedchem.5b00626. Epub 2015 Jun 26. PMID: 26083478 4:CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mortensen DS, Fultz KE, Xu S, Xu W, Packard G, Khambatta G, Gamez JC, Leisten J, Zhao J, Apuy J, Ghoreishi K, Hickman M, Narla RK, Bissonette R, Richardson S, Peng SX, Perrin-Ninkovic S, Tran T, Shi T, Yang WQ, Tong Z, Cathers BE, Moghaddam MF, Canan SS, Worland P, Sankar S, Raymon HK.Mol Cancer Ther. 2015 Jun;14(6):1295-305. doi: 10.1158/1535-7163.MCT-14-1052. Epub 2015 Apr 8. PMID: 25855786 Free Article